Ranbaxy exploited the FDA’s “abbreviated new drug applications” (ANDAs) in order to secure valuable first-to-file generic status and lucrative 180-day exclusivity that comes with the first-to-file status.
Continue reading Attention Plan Sponsors – Stake Your Claim To $485 Million Rx Settlement